U of Minn. sets new conflicts policy; Wellbutrin fuels 23% sales boost at Biovail;

 @FiercePharma: NEJM study cuts epilepsy meds' link to suicide. Article |  Follow @FiercePharma

> Joining a small, but growing list of academic institutions, the University of Minnesota has adopted new rules governing conflicts of interest for its medical school employees. Item

> Biovail reported a rise in second-quarter profit, as revenues increased 23 percent, driven by higher sales of its antidepressant Wellbutrin. News

> MedImmune has chosen a Genentech marketing executive, Scott Carmer, to head up its global commercial operations. Report

> Sanofi-Aventis has hired Ian Weatherhead, formerly of UCB, as director of communications. Article

> Poland's treasury ministry and the pharmaceuticals group Polski Holding Farmaceutyczny have decided to sell off the latter's subsidiary, Polfa Tarchomin. Story

> Sanofi-Aventis has won the FDA's nod for a new one-vial formulation of its chemotherapeutic agent Taxotere. Report

> A Jefferies & Co. analyst downgraded Eli Lilly shares, citing patent lawsuits and a lack of upcoming events from the company's product pipeline. Article

Biotech News

 @FierceBiotech: PwC sees big 2Q jump in biotech venture investments. Article | Follow @FierceBiotech

 @JohnCFierce: Reuters reduced to quoting Genzyme staffer fearing layoffs in a post-merger world. What, no new insider leaks? Article | Follow @JohnCFierce

> GSK licenses Vectura's inhalation tech for $32 million. Story

> Cypress rebuffs Ramius buyout offer. News

> NuPathe's price cut shows slow biotech IPO recovery. Article

> GenVec, Novartis ink clinical trials supply deal. Item

> Seattle Genetics preps for busy fall. Report

> Janssen gets Acuform tech rights. Story

And Finally... With the district in a financial crisis and hundreds of its members facing layoffs, the Milwaukee teachers union is taking a peculiar stand: fighting to get their taxpayer-funded Viagra back. Feature